SCHEMBL143364

SCHEMBL143364

CC(C)OC(=O)NNC(=O)OC(C)C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.50
HPGD P15428 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
NPC1 O15118 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
RAB9A P51151 1/20 0.42
KDM4E B2RXH2 1/20 0.39
CA12 O43570 6/20 0.39
CA1 P00915 6/20 0.39
CA2 P00918 6/20 0.39
CA9 Q16790 6/20 0.39
CA7 P43166 5/20 0.39
CA14 Q9ULX7 5/20 0.39
HCAR2 Q8TDS4 1/20 0.39
ALOX15 P16050 2/20 0.38
HTT P42858 1/20 0.37
GAA P10253 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11651635 0.92 TSHR (0.43) TSHRHPGDSMN1; SMN2NPC1CYP1A2
SCHEMBL19508782 0.92 TSHR (0.43) TSHRHPGDSMN1; SMN2NPC1CYP1A2
SCHEMBL19106903 0.92 TSHR (0.43) TSHRHPGDSMN1; SMN2NPC1CYP1A2
SCHEMBL1142641 0.89 TSHR (0.42) TSHRHPGDSMN1; SMN2NPC1CYP1A2
Water SCHEMBL11650852 0.89 TSHR (0.42) TSHRHPGDSMN1; SMN2NPC1CYP1A2
SCHEMBL24635151 0.89 TSHR (0.48) TSHRHPGDSMN1; SMN2NPC1CYP1A2
SCHEMBL19509181 0.89 TSHR (0.42) TSHRHPGDSMN1; SMN2NPC1CYP1A2
SCHEMBL17280409 0.87 TSHR (0.40) TSHRHPGDSMN1; SMN2NPC1CYP1A2
SCHEMBL20807295 0.86
SCHEMBL10676068 0.84 TSHR (0.42) TSHRHPGDSMN1; SMN2NPC1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 261 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279214-A1 FOAMABLE ACRYLIC COMPOSITION ARKEMA FRANCE (FR) 2023-09-07 US claimed
EP-3717554-A1 FOAMABLE ACRYLIC COMPOSITION Arkema, Inc. (US) 2020-10-07 EP claimed
US-20200282689-A1 MULTI-LAYER FLUOROPOLYMER FOAM STRUCTURE ARKEMA INC (US) 2020-09-10 US claimed
EP-2888515-A2 MULTI-LAYER FLUOROPOLYMER FOAM STRUCTURE Arkema, Inc. (US) 2015-07-01 EP claimed
WO-2014031510-A2 MULTI-LAYER FLUOROPOLYMER FOAM STRUCTURE ARKEMA INC. (US) 2014-02-27 WO claimed
US-20130108816-A1 MULTI-LAYER FLUOROPOLYMER FOAM STRUCTURE ARKEMA INC. (US) 2013-05-02 US claimed
EP-0214552-B1 FOAMABLE MOLDINGS COMPOSITIONS MOBAY CORPORATION (US) 1990-09-26 EP claimed
US-4737523-A BLEND CONTAINING ANHYDRIDE-IMPACT RESISTANCE MOBAY CORPORATION (US) 1988-04-12 US claimed
US-4675345-A JACKETS AND COATINGS FOR CABLES AND TELEPHONE WIRES; DIELECTR ICS PENWALT CORPORATION (US) 1987-06-23 US claimed
EP-0214552-A2 Foamable moldings compositions MOBAY CORPORATION (US) 1987-03-18 EP claimed
US-4615850-A BLENDING WITH NUCLEATING AGENT, BLOWING AGENT; EXTRUSION PENNWALT CORPORATION (US) 1986-10-07 US claimed
EP-0169304-A1 Foamable polyvinylidene fluoride and a method for producing it PENNWALT CORPORATION (US) 1986-01-29 EP claimed
US-4394460-A WIRE COATINGS ALLIED CORPORATION (US) 1983-07-19 US claimed
US-20260144795-A1 SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS H. LUNDBECK A/S (DK) 2026-05-28 US disclosed
EP-4720076-A1 SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS H. Lundbeck A/S (DK) 2026-04-08 EP disclosed
US-12590106-B2 Spiromacrocyclic orexin 2 receptor agonists H. LUNDBECK A/S (DK) 2026-03-31 US disclosed
US-4334030-A INJECTION MOLDABLE CONCENTRATES CONTAINING AMIDE DERIVATIVES OF AZODICARBOXYLIC ACID AND A DIHYDROOXADIAZINONE AS BLOWING AGENTS GENERAL ELECTRIC COMPANY (US) 1982-06-08 US disclosed
US-4331619-A Ethylene-chlorotrifluoroethylene copolymer foam ALLIED CORPORATION (US) 1982-05-25 US disclosed
US-4163037-A USING A DIHYDROOXADIAZINONE BLOWING AGENT, INJECTION MOLDING GENERAL ELECTRIC COMPANY (US) 1979-07-31 US disclosed
US-4097425-A POLYCARBONATES, POLYESTERS, SUBSTITUTED 3,6-DIHYDRO-1,3,4-OXDIAZIN-2-ONE GENERAL ELECTRIC COMPANY (US) 1978-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260144795-A1 SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS HCRTR2, HCRTR1, CRHR1 TSHR 119/4885HPGD 1531/4885SMN1; SMN2 2566/4885
US-12590106-B2 Spiromacrocyclic orexin 2 receptor agonists HCRTR2, HCRTR1, OXER1 TSHR 255/4885HPGD 499/4885SMN1; SMN2 2624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.